



2021 Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting (Boston, MA and Virtual): Eisai Oral Presentations and Posters

Please see the Eisai oral presentations and posters presented at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) annual meeting listed below and refer to the Congress Links section available on our Medical Information website which may include additional information.

Lecanemab (BAN2401)

1. Dhadda S, Kanekiyo M, Li D, et al. Consistency of Efficacy Assessments Across Various Statistical Methods from the Lecanemab Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects with Early Alzheimer's Disease. Oral presentation presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.
2. Lynch SY, Gee M, Kanekiyo M, et al. Baseline Characteristics for Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401) in Early Alzheimer's Disease. Oral presentation presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.
3. Lynch SY, Gee M, Kanekiyo M, et al. A Stepwise Tier-Based Approach for Determining Patient Eligibility in Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind Study to Confirm the Safety and Efficacy of Lecanemab (BAN2401) 10 mg/kg Biweekly in Patients with Early Alzheimer's Disease. Oral presentation presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.
4. Sperling R, Johnson K, Zhou J, et al. Introduction of Plasma Biomarker Screening for the AHEAD 3-45 Study. Oral presentation presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.
5. Swanson CJ, Dhadda S, Irizarry M, et al. Clinical, Biomarker, and Safety Update from the Lecanemab Phase 2 Study. Oral presentation presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.

General Alzheimer's disease

1. Doherty T, Smith R, Smith MT, et al. Improving Screening Efficiency through Alternate Story Recall. Poster presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.
2. Karten Y, Sivakumaran S, Cui Z, et al. CPAD: Accelerating Alzheimer's Disease Drug Development through Pre-Competitive Data Sharing and Generation of Data-Driven Quantitative Drug Development Tools. Poster presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.
3. Monfared AAT, Doogan S, Farid N, et al. Decision-Making and Reactions on Genetic Testing in Alzheimer's Disease among Patients, Caregivers, and Healthcare Professionals. Poster presented at: Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting; November 9-12, 2021; Boston, MA and Virtual.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the poster(s) listed above, please submit your request via www.eisaimedicalinformation.com/neurology/medicalinquiry or the Submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_medinfo@eisai.com or call 1-888-274-2378.